Your browser doesn't support javascript.
loading
Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial.
Ignatiadis, M; Litière, S; Rothe, F; Riethdorf, S; Proudhon, C; Fehm, T; Aalders, K; Forstbauer, H; Fasching, P A; Brain, E; Vuylsteke, P; Guardiola, E; Lorenz, R; Pantel, K; Tryfonidis, K; Janni, W; Piccart, M; Sotiriou, C; Rack, B; Pierga, J-Y.
Afiliação
  • Ignatiadis M; Department of Medical Oncology, Institut Jules Bordet, Universite ´ Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory J. C. Heuson, Institut Jules Bordet, Universite ´ Libre de Bruxelles, Brussels, Belgium. Electronic address: michail.ignatiadis@bordet.be.
  • Litière S; European Organization for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium.
  • Rothe F; Breast Cancer Translational Research Laboratory J. C. Heuson, Institut Jules Bordet, Universite ´ Libre de Bruxelles, Brussels, Belgium.
  • Riethdorf S; Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Proudhon C; Circulating Tumor Biomarker Laboratory, Institut Curie, Paris, France.
  • Fehm T; Department of Gynecology and Obstetrics, Universitätsklinikum, Düsseldorf, Germany.
  • Aalders K; European Organization for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium.
  • Forstbauer H; Society for Oncological Studies, Praxismanagement und -Logistik (GOSPL), Troisdorf, Germany.
  • Fasching PA; Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
  • Brain E; Department of Medical Oncology, Institut Curie, Saint-Cloud, France.
  • Vuylsteke P; Université catholique de Louvain, CHU Ucl Namur, Belgium.
  • Guardiola E; Hospital Center of Dracénie, Draguignan, France.
  • Lorenz R; Gynecological Clinic Lorenz/Hecker/Wesche, Braunschweig, Germany.
  • Pantel K; Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Tryfonidis K; European Organization for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium.
  • Janni W; Department of Gynecology and Obstetrics, Universitaetsklinikum Ulm, Ulm, Germany.
  • Piccart M; Department of Medical Oncology, Institut Jules Bordet, Universite ´ Libre de Bruxelles, Brussels, Belgium.
  • Sotiriou C; Department of Medical Oncology, Institut Jules Bordet, Universite ´ Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory J. C. Heuson, Institut Jules Bordet, Universite ´ Libre de Bruxelles, Brussels, Belgium.
  • Rack B; Department of Gynecology and Obstetrics, Universitaetsklinikum Ulm, Ulm, Germany.
  • Pierga JY; Circulating Tumor Biomarker Laboratory, Institut Curie, Paris, France; Department of Medical Oncology, Institut Curie, Université Paris Descartes, Paris, France.
Ann Oncol ; 29(8): 1777-1783, 2018 08 01.
Article em En | MEDLINE | ID: mdl-29893791
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Trastuzumab / Antineoplásicos Imunológicos / Células Neoplásicas Circulantes Tipo de estudo: Clinical_trials / Etiology_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Trastuzumab / Antineoplásicos Imunológicos / Células Neoplásicas Circulantes Tipo de estudo: Clinical_trials / Etiology_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article